retatrutide trial weight loss results Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide approval: FDA status, clinical
Description
Glucagon Receptor Agonism (GCGR) The inclusion of the Glucagon receptor is what distinguishes Retatrutide from Tirzepatide
Acting on these receptors helps control appetite and reduce food intake, promoting significant weight loss
This allows for more controlled comparisons within defined experimental parameters
And conveniently, theyre the ones who decide which trials get funded
Cole, T
